Short term effectiveness of ustekinumab versus vedolizumab in Crohn’s disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis

Crohn's disease (CD) is a debilitating gastrointestinal disease with complex etiology. Although effective, recipients of anti-tumor necrosis factor (TNF) agents may experience primary or secondary nonresponse, necessitating alternative treatments. This study is intended to compare the short-term effectiveness of ustekinumab and vedolizumab in treating CD after failure of multiple lines of anti-TNF therapy using real-world data.